prikaz prve stranice dokumenta Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?
  Download
PDF 420.16 KB
Scientific paper - Original scientific paper
Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?
International Journal of Environmental Research and Public Health, 17 (2020), 18; 6566. https://doi.org/10.3390/ijerph17186566
Lekšić, Gloria; Baretić, Maja; Ivanišević, Marina; Jurišić Eržen, Dubravka

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Lekšić, G., Baretić, M., Ivanišević, M. & Jurišić Eržen, D. (2020). Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?. International Journal of Environmental Research and Public Health, 17. (18). doi: 10.3390/ijerph17186566

Lekšić, Gloria, et al. "Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?." International Journal of Environmental Research and Public Health, vol. 17, no. 18, 2020. https://doi.org/10.3390/ijerph17186566

Lekšić, Gloria, Maja Baretić, Marina Ivanišević and Dubravka Jurišić Eržen. "Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?." International Journal of Environmental Research and Public Health 17, no. 18 (2020). https://doi.org/10.3390/ijerph17186566

Lekšić, G., et al. (2020) 'Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?', International Journal of Environmental Research and Public Health, 17(18). doi: 10.3390/ijerph17186566

Lekšić G, Baretić M, Ivanišević M, Jurišić Eržen D. Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?. International Journal of Environmental Research and Public Health [Internet]. 2020 September 09 [cited 2024 December 25];17(18). doi: 10.3390/ijerph17186566

G. Lekšić, M. Baretić, M. Ivanišević and D. Jurišić Eržen, "Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?", International Journal of Environmental Research and Public Health, vol. 17, no. 18, September 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:529488. [Accessed: 25 December 2024]

Metadata
Title (english)Pregnancy in Patients with Type One Diabetes Mellitus Treated with Continuous Subcutaneous Insulin Infusion—Preconception Basal Insulin Dose as a Potential Risk Factor for Fetal Overgrowth?
AuthorGloria Lekšić
AuthorMaja Baretić
AuthorMarina Ivanišević
AuthorDubravka Jurišić Eržen
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Gynecology and Obstetrics
Abstract (english)
Despite widespread use of technology, type one diabetes mellitus (T1DM) is still a great clinical challenge during pregnancy. This study aims to assess how prenatal variables of T1DM patients using continuous subcutaneous insulin infusion (CSII) influence pregnancy outcomes. We performed a retrospective study of 35 patients with T1DM treated with CSII during pregnancy. Alterable preconception variables (A1C, body mass index, basal and bolus insulin dose) were analysed as possible contributors to birth weight and large-for-gestational-age (LGA) prevalence. Inclusion criteria were presence of T1DM for more than two years, A1C < 7.4% and treatment with CSII for at least three months prior to conception. The preconception basal insulin dose and A1C had a significant correlation to the neonatal birth weight (p = 0.01, r = 0.4 and p = 0.04, r = 0.3, respectively) and were significant in regression analysis together contributing 22% of the variance in birth weight percentiles (sig = 0.17, R square = 0.22). Prevalence of LGA was 46%. Women who had LGA neonates also had a higher preconception basal insulin dose compared to women with non-LGA neonates (26 ± 9 vs. 18 ± 7 IU (international units), p = 0.01). The LGA group had a higher preconception A1C, but it did not reach statistical significance (6.5 ± 0.5% vs. 6.2 ± 0.9%, respectively, p = 0.2). Women with T1DM treated with CSII who had unregulated glycaemia and more basal insulin were at greater risk for development of LGA neonates.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleInternational Journal of Environmental Research and Public Health
Numberingvol. 17, no. 18, 6566
e-ISSN1660-4601
DOIhttps://doi.org/10.3390/ijerph17186566
URN:NBNurn:nbn:hr:184:529488
Publication2020-09-09
Document URLhttps://www.mdpi.com/1660-4601/17/18/6566
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2020-09-28 14:51:26